AlzoSure Predict uses an antibody (U-p53AZ) for measuring blood levels of a conformational variant of the p53 protein. Credit: Diadem srl / PRNewswire.

Diadem and Quest Diagnostics have signed an exclusive US licensing agreement for the former’s AlzoSure Predict Alzheimer’s Disease (AD) prognostic technology.

Quest has obtained exclusive rights to the intellectual property of the blood-based prognostic technology to develop, validate and market a laboratory-developed test service for providers and patients in the country.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

AlzoSure Predict utilises an antibody (U-p53AZ) for measuring blood levels of a conformational variant of the p53 protein implicated in the pathogenesis of AD.

Its utility is backed by clinical data from a longitudinal study, leading to its designation as a breakthrough device by the US Food and Drug Administration and its CE-IVD marking in the EU.

The non-invasive technology can identify the risk of AD in its asymptomatic and early symptomatic stages with just 1ml of blood.

See Also:

It can detect people with a high likelihood of developing the disease within a two-year timeframe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Research has also shown that the technology can distinguish between various types of dementia.

Diadem CEO Paul Kinnon said: “The decade of work by our researchers and collaborators to clinically validate this important technology is bearing fruit as new therapies and growing knowledge about Alzheimer’s disease are providing hope that early interventions may slow or stop disease progression.

“We see AlzoSure Predict as a potentially valuable contributor in this effort and view Quest as the ideal collaborator to help make the benefits of the AlzoSure technology widely available to patients and their healthcare providers as part of Quest’s quality test portfolio.”